Peer-reviewed veterinary case report
Development of <sup>225</sup>Ac Production from Low Isotopic Dilution <sup>229</sup>Th.
- Year:
- 2023
- Authors:
- Camacaro JF et al.
- Affiliation:
- TerraPower LLC · United States
Abstract
The promise of <sup>225</sup>Ac targeted alpha therapies has been on the horizon for the last two decades. TerraPower Isotopes are uniquely suited to produce clinically relevant quantities of <sup>225</sup>Ac through the decay of <sup>229</sup>Th. Herein, a rapid processing scheme to isolate radionuclidic and radioisotopically pure <sup>225</sup>Ac in good yield (98%) produced from <sup>229</sup>Th that contains significant quantities of <sup>228</sup>Th activity is described. The characterization of each step of the process is presented along with the detailed characterization of the resulting <sup>225</sup>Ac isotopic starting material that will support the cancer research and development efforts.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication: https://europepmc.org/article/MED/37901510